Search results
Results from the WOW.Com Content Network
The Company cited the risk of the label is missing on some prefilled pens contained inside labeled cartons of the drug. The recall doesn't cover Viatris' recently launched interchangeable Semglee ...
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. [2] ...
Novo has filed several U.S. patent lawsuits against companies including Pennsylvania-based Viatris that are seeking to market generic versions of the drugs. Viatris has separately asked a West ...
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn , a legacy division of Pfizer , on November 16, 2020.
Falling by about 23% right after the news, and down around 32.5% in the past month, it may take some time for Viatris to bounce back. Another generic drug maker, Teva Pharmaceutical (NYSE:TEVA ...
There was a second issue that levothyroxine preparations were not properly stable, resulting in recalls. The FDA required a NDA (new drug application) to resolve the second of these issues, which led to synthroid (amongst others) being reformulated to improve its stability.
(Reuters) -Viatris unit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry, the parent company said on ...
A drug recall removes a prescription or over-the-counter drug from the market. Drug recalls in the United States are made by the FDA or the creators of the drug when certain criteria are met. When a drug recall is made, the drug is removed from the market and potential legal action can be taken depending on the severity of the drug recall. [1]